Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.
Forty years after the release of Atwood’s seminal novel, we are witnessing the echoes of real-life horror stories that inspired her to tell the tale.
The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...
6h
Barchart on MSNHow Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
2d
US Weekly on MSNHulu Is Close to Giving ‘Handmaid’s Tale’ Spinoff ‘The Testaments’ a Series Order After New CastingHulu is nearing a series order for 'The Handmaid’s Tale' spinoff 'The Testaments' before the hit show's final season ...
When asked about each segment of ESG, almost all of the surveyed groups, 94%, said that the impact a pharma has on society is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results